CSIMarket Company Name, Ticker, Industry, else..
 
Salarius Pharmaceuticals inc   (NASDAQ: SLRX)
Other Ticker:  
 
 
Price: $1.5300 $0.06 4.082%
Day's High: $1.53 Week Perf: 0.66 %
Day's Low: $ 1.53 30 Day Perf: 3.38 %
Volume (M): 3 52 Wk High: $ 7.20
Volume (M$): $ 4 52 Wk Avg: $3.18
Open: $1.53 52 Wk Low: $1.26



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 1
 Employees 8
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of targeted therapies for pediatric and adult cancers. The company is dedicated to improving the lives of cancer patients through the creation of innovative treatments that address unmet medical needs. Salarius Pharmaceuticals aims to leverage its expertise in epigenetics and gene regulation to develop effective and safe therapies.


   Company Address: 2450 Holcombe Blvd Houston 77021 TX
   Company Phone Number: 804-9144   Stock Exchange / Ticker: NASDAQ SLRX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD   -0.37%    
BMY        0.08% 
REGN        5.42% 
SUPN        5.42% 
UTHR        5.42% 
VRTX        5.42% 
• View Complete Report
   



Stocks on the Move

Understanding the Factors Behind Salarius Pharmaceuticals? Recent Stock Sell-Off From Stock Offerings to Regulatory Challenges,

Published Thu, Aug 8 2024 3:26 PM UTC

What is Behind Today s Sell-Off in Salarius Pharmaceuticals Inc Shares In a week marked by volatility for Salarius Pharmaceuticals Inc (NASDAQ: SLRX), the recent sell-off in its stock has raised eyebrows among investors and market analysts alike. Following a tumultuous series of news events, the stock experienced significant fluctuations, culminating in a sharp decline as ...
Stocks on the Move

Sailing Through Challenges Salarius Pharmaceuticals Inc Faces FDA Hurdle, Yet Earns Analysts Buy Rating, with Strong Growth Prospects and Potential Market Resilienc...

Published Tue, Jul 16 2024 11:50 AM UTC

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) has recently been in the spotlight due to various news events that have impacted its stock performance and market outlook. In this article, we will delve into the key highlights of each news item and provide an analysis of their potential implications. Additionally, we will assess the overall performance of Salarius Pharmaceuticals...
Stocks on the Move

Salarius Pharmaceuticals Faces Stock Market Challenges Amidst Promising Developments

Published Tue, Jun 25 2024 3:08 PM UTC

In the fast-paced world of biopharmaceuticals, companies often have to navigate through stock market challenges while striving to develop innovative therapies. Salarius Pharmaceuticals Inc (NASDAQ: SLRX) is no exception, as it recently encountered a decline in stock prices alongside significant developments in its quest to revolutionize cancer treatments. Despite volatile ma...
Clinical Study

Seclidemstat and Azacitidine Combination Therapy Shows Promising Results in the Treatment of Myelodysplastic Syndrome...

Published Mon, Jun 17 2024 12:01 PM UTC

In recent years, the treatment landscape for hematological malignancies has witnessed significant advancements. Among these, targeted therapies have emerged as potential game-changers due to their ability to selectively inhibit key molecular pathways involved in cancer progression. One such promising combination therapy, involving Salarius Pharmaceuticals' seclidemstat and a...
Stock Market Announcement

Salarius Pharmaceuticals Initiates 1-for-8 Reverse Stock Split, Paving the Way for Enhanced Shareholder Value

Published Wed, Jun 12 2024 12:00 PM UTC


Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, has recently made a significant announcement that is set to reshape its stock trading on the Nasdaq Capital Market. On June 14, 2024, the company will implement a 1-for-8 reverse stock split, marking a pivotal moment in its trajectory. This move is exp...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com